Moreover, inhibition of ubiquitin-specific protease 22 (USP22) reduces de novo fatty acid synthesis and mitigate HCC tumorigenesis, which is largely achieved through suppressing ACC and ACLY through inhibiting the expression of peroxisome proliferators-activated receptor (PPAR) [36]. The gene discussed is ACLY; the disease is hepatocellular carcinoma.